Drug firm Strides Pharma Science Tuesday said it has received establishment inspection report (EIR) from the US health regulator for its Singapore facility.
The company had earlier in March announced receiving approval from the United States Food and Drug Administration (USFDA) for the greenfield oral dosage facility in Singapore.
The company has now received the EIR there by confirming the successful closure of the inspection, which concluded on February 1, 2019, Strides Pharma Science said in a BSE filing.
The facility has already been approved by Health Science Authority (HSA) Singapore and Therapeutic Goods Administration (TGA) Australia.
Shares of Strides Pharma Science Ltd closed at Rs 474.20 per scrip on BSE, down 0.45 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app